Fig. 6
From: Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile
ttIL-12 prolonged survival compared to wtIL-12 in two independent mouse tumor models and a human tumor model. Overall survival of tumor-bearing mice treated with empty plasmid DNA (pDNA; pCtrl), wild-type IL-12 pDNA (pwtIL-12), tumor-targeted IL-12 pDNA (pttIL-12), or pttIL-12 plus a CD8-depleting antibody (pttIL-12 + αCD8a) was determined by using the Kaplan-Meier analysis. Treatment strategy was as described in Fig. 2a. a Overall survival of 4 T1 tumor–bearing mice by treatment group. b Overall survival of LM8 tumor–bearing mice. c Overall survival of LM8 tumor–bearing mice treated with an extra administration of pDNA 15 days after primary tumor removal. (D) Overall survival of OS60-SJ osteosarcoma patient-derived xenograft (PDX) tumor-bearing mice overall survival. The dark arrows represent pDNA treatment, the blue arrows represent primary tumor removal, and the red arrows represent PBMC injections. Data represent cumulative results from at least two independent experiments. *P < 0.05, **P < 0.01***P < 0.001, ****P < 0.0001